media – Page 23 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HRS-1167 tablets clinical trial approved

On April 20, the company announced that HRS-1167 tablets obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration and will conduct clinical trials in the near future. HRS-1167 tablets are highly selective, highly active, and orally available PARP1 small molecule inhibitors independently developed by the company with intellectual property rights. They belong to the second generation of PARP inhibitors. Compared with the first generation of PARP inhibitors, HRS-1167 has higher selectivity and stronger affinity for PARP1. HRS-1167 is currently in the early clinical development stage and has the potential to be used as a monotherapy and combination therapy to treat more patients, including tumor patients who were previously unable to use PARP inhibitors. Upon inquiry, no similar products have been approved for marketing at home and abroad. As of now, the R&D expenses of HRS-1167 tablets related projects have accumulated to approximately RMB 72.11 million. ...
- Source: drugdu
- 139
- April 22, 2025
Watson Bio’s 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials

On April 18, Watson Bio (300142) issued an announcement that the 20-valent pneumococcal polysaccharide conjugate vaccine jointly applied for clinical trials by the company and its subsidiaries has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, with the notice number: 2025LP01099. The clinical trial of this vaccine will target children aged 2 months (minimum 6 weeks old) to 5 years old to prevent infectious diseases caused by the 20 pneumococcal serotypes contained in this product. This vaccine is an iterative upgrade based on the company’s already marketed 13-valent pneumococcal polysaccharide conjugate vaccine, with 7 new serotypes added. At present, only Pfizer in the United States has launched a 20-valent pneumococcal polysaccharide conjugate vaccine in the world, and there are no related products in China. In 2024, Watson Bio achieved revenue of 2.821 billion yuan and net profit attributable to shareholders of the parent company ...
- Source: drugdu
- 125
- April 22, 2025
Flu vaccine started a “price war”, Jindik failed to get out of the loss

In 2024, Jindik achieved operating income of 80.8027 million yuan, a year-on-year decrease of 39.96%, and lost money for the second consecutive year. At present, Jindik has only one product on the market, namely the quadrivalent influenza virus split vaccine. In 2024, the price of this product was reduced by 30%, directly falling below 100 yuan. Profitability was weakened and sales expenses accounted for too high a proportion, both dragging down the company’s performance. In order to get rid of dependence on a single product, Jindik has increased its R&D investment. At present, the rabies vaccine product has completed Phase III clinical trials and is in the process of product registration and declaration. Flu vaccine followed the trend of price reduction, and sales volume and price fell in one year In 2024, Jindik not only failed to reverse the loss, but fell deeper and deeper. On April 17, the company ...
- Source: drugdu
- 114
- April 22, 2025
APHM CMEF Malaysia

Organiser：Reed Sinopharm Exhibitions, APHM Time：June 9-11, 2025 address：50088 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Jalan Pinang, Kuala Lumpur City Centre Exhibition hall：Kuala Lumpur Convention Centre, Malaysia Product range: Medical and Hospital Equipment & Machinery: Diagnostic equipment and supplies, dental products, consumables, emergency equipment, disposable items, hospital information systems, medical staff uniforms, nursing supplies, etc. Electronic Medical Equipment: Instruments, blood pressure monitors, laser equipment, surgical tools, scanning devices, etc. Medical Laboratories: Analytical instruments, microbiology, analysis, biochemical equipment, etc. Pharmaceutical Machinery: Bioengineering, finished pharmaceuticals, pharmaceutical raw materials, pharmaceutical processing, pharmaceutical packaging, pharmaceutical services, analytical and testing instruments, pharmaceutical laboratory equipment, etc. Rehabilitation and Home Care: Assistive and physical devices, rehabilitation equipment, orthopedic devices, sports facilities, wheelchairs, fitness equipment Aesthetic and Medical Beauty-Related Products: Biotechnology products, diagnostic and testing instruments, beauty products, aesthetic equipment, dressings and consumables, anti-aging medical products, related technologies and services, etc. About APHM CMEF Malaysia： The APHM ...
- Source: drugdu
- 130
- April 22, 2025
Kangtai Biological’s revenue in the first quarter of 2025 increased by more than 40% year-on-year, and multiple projects such as the pentavalent vaccine made significant progress

The evening of April 20, Kangtai Biological (300601) released its 2024 annual report and 2025 first quarter report. The company achieved operating income of 2.652 billion yuan in 2024 and a net profit of 246 million yuan attributable to the parent company after deducting non-recurring items; operating income in the first quarter of 2025 was 645 million yuan, a year-on-year increase of 42.85%; net profit attributable to the parent company after deducting non-recurring items was 17 million yuan, a year-on-year increase of 17.56%. The annual report shows that Kangtai Biological’s R&D investment in 2024 was 569 million yuan, accounting for 21.47% of the operating income of the year, and the cumulative R&D investment in the past three years was 2.105 billion yuan, accounting for 22.67% of the cumulative operating income in the past three years. During the reporting period, Kangtai Biological’s new vaccine R&D pipeline has made a number of ...
- Source: drugdu
- 150
- April 21, 2025
The national immunization program will enter a period of dynamic adjustment, and many new vaccines are expected to be included

On the morning of April 19, the 2025 Vaccine and Health Conference was held. Shen Hongbing, deputy director of the National Health Commission and director of the National Disease Control Bureau, shared his outlook and ideas on the future adjustment model of the national immunization program in his speech. Shen Hongbing said that one direction in the future is to dynamically adjust and optimize the national immunization program strategy, and optimize it according to the principles of overall planning, dynamic adjustment, and step-by-step implementation. “We are preparing to make a five-year plan,” he said. The future goal is to gradually narrow the gap between the domestic immunization program and the international level, and gradually include vaccines that need to be included. The last time China substantially included a new vaccine was in 2007. The adjustments in recent years mainly involve vaccination procedures and strategies. Therefore, there is a gap between ...
- Source: drugdu
- 169
- April 21, 2025
Beike Biotech’s revenue and net profit both fell, sales of herpes zoster vaccines decreased, and the core of marketing left

On the evening of April 20, Beike Biotech (688276) released its 2024 annual report showing that during the reporting period, the company’s operating income was approximately 1.229 billion yuan, a year-on-year decrease of 32.64%; the corresponding attributable net profit was approximately 232 million yuan, a year-on-year decrease of 53.67%. It is planned to pay a cash dividend of 1.69 yuan (including tax) per 10 shares to all shareholders. In this regard, the annual report pointed out that the main reason was the decrease in revenue and net profit due to the decrease in sales of herpes zoster vaccines during the reporting period; the net cash flow generated by operating activities was 406.5022 million yuan, 255.2070 million yuan in the same period last year, an increase of 59.28%, mainly due to the increase in sales proceeds; basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring ...
- Source: drugdu
- 152
- April 21, 2025
High incidence recently, no vaccine to prevent! Guangdong reports 1542 cases of scarlet fever

Recently, the number of cases of scarlet fever in Guangdong, Hunan and other places has increased. In the absence of an effective vaccine, how to correctly understand scarlet fever and scientifically prevent it has received high attention. On April 14, the Guangdong Provincial Disease Control and Prevention Bureau announced the provincial statutory infectious disease epidemic situation in March 2025. Among them, the number of scarlet fever cases reported in Guangdong Province in March was 1542, an increase of 641 cases from February. On April 17, Hu Yan, deputy director of the Children’s Medical Center of the First Affiliated Hospital of Hunan University of Chinese Medicine, said that the number of children with scarlet fever seen in the hospital’s pediatric outpatient and emergency departments has increased recently. “This year’s spring in the south is relatively dry, which is conducive to the survival and spread of group A hemolytic streptococci.” On April ...
- Source: drugdu
- 137
- April 21, 2025
【EXPERT Q&A】Medical devices have high requirements for the stability and safety of PCBA. What are the key control points in the development and production process?

Drugdu.com expert’s response: In the research, development, and production process of Printed Circuit Board Assembly (PCBA) for medical devices, stability and safety are core requirements. To ensure that products meet the high standards of the medical industry, strict controls must be implemented across multiple dimensions, including design, materials, manufacturing processes, testing, regulatory compliance, and supply chain management. The following is a detailed analysis of key control points: I. Design Phase Functional Safety Design Employ redundant design, fail-safe mechanisms, and fault-tolerant design to ensure that a single failure does not lead to system failure. Conduct risk analysis (e.g., FMEA, FTA) to identify potential failure modes and develop mitigation measures. Electromagnetic Compatibility (EMC) Design Optimize circuit layout to reduce electromagnetic interference (EMI) and radio frequency interference (RFI). Select low-emission components and incorporate shielding and filtering designs to ensure stable operation in complex electromagnetic environments. Thermal Design and Reliability Assessment Analyze key component ...
- Source: drugdu
- 140
- April 21, 2025
【EXPERT Q&A】What problems should domestic pharmaceutical and medical equipment enterprises pay attention to in export?

Drugdu.com expert’s response: When domestic pharmaceutical and medical device enterprises engage in foreign trade exports, they need to focus on core issues such as policy regulations, market demand, product quality, certification and compliance, and branding and after-sales service to ensure the smooth progress of export business. Below are specific considerations: I. Policy Regulations and Compliance Requirements Target Market Regulations Different countries have significantly varying regulatory standards for medical devices. For example, the EU requires compliance with CE certification and MDR regulations, while the US requires FDA 510(k) registration or PMA approval. Enterprises must understand the regulatory requirements of the target market in advance to avoid product rejection due to compliance issues. Domestic Export Policies Enterprises need to obtain medical device registration certificates and production licenses issued by the National Medical Products Administration (NMPA) and handle import-export business licenses. Special medical devices (such as COVID-19 testing reagents) may require additional export ...
- Source: drugdu
- 103
- April 18, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.